Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. (Q50896060)

24 March 2018

title

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. (English)

1 reference

24 March 2018

multicenter clinical trial

main subject

Helicobacter pylori

0 references

1 reference

1 reference

Jyh-Ming Liou

1

1 reference

24 March 2018

Chieh-Chang Chen

2

1 reference

24 March 2018

Mei-Jyh Chen

3

1 reference

24 March 2018

Chien-Chuan Chen

4

1 reference

24 March 2018

Chi-Yang Chang

5

1 reference

24 March 2018

Yu-Jen Fang

6

1 reference

24 March 2018

Ji-Yuh Lee

7

1 reference

24 March 2018

Shih-Jer Hsu

8

1 reference

24 March 2018

Jiing-Chyuan Luo

9

1 reference

24 March 2018

Wen-Hsiung Chang

10

1 reference

24 March 2018

Yao-Chun Hsu

11

1 reference

24 March 2018

Cheng-Hao Tseng

12

1 reference

24 March 2018

Ping-Huei Tseng

13

1 reference

24 March 2018

Hsiu-Po Wang

14

1 reference

24 March 2018

Ueng-Cheng Yang

15

1 reference

24 March 2018

Chia-Tung Shun

16

1 reference

24 March 2018

Jaw-Town Lin

17

1 reference

24 March 2018

Yi-Chia Lee

18

1 reference

24 March 2018

Ming-Shiang Wu

19

1 reference

24 March 2018

Taiwan Helicobacter Consortium

20

1 reference

24 March 2018

language of work or name

English

0 references

publication date

16 November 2012

1 reference

24 March 2018

published in

The Lancet

1 reference

24 March 2018

volume

381

1 reference

24 March 2018

issue

9862

1 reference

24 March 2018

page(s)

205-213

1 reference

24 March 2018

Helicobacter pyloriInfection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

New concepts of resistance in the treatment of Helicobacter pylori infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Clarithromycin-resistant genotypes and eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Sequential regimens for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Sequential therapy for Helicobacter pylori: time to consider making the switch?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Genetic determinants of warfarin dosing in the Han-Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Eradication therapy for Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

Diagnosis of Helicobacter pylori: invasive and non-invasive tests

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961579-7

7 January 2021

10.1016/S0140-6736(12)61579-7

Identifiers

DOI

1 reference

24 March 2018

PubMed ID

23158886

1 reference

24 March 2018